CPRIT approves $154 million in new cancer research and prevention awards, surpasses $4 billion total
On Nov. 19, 2025, the governing board of the Cancer Prevention and Research Institute of Texas (CPRIT) approved…
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection
On Oct. 18, 2025, GRAIL announced that positive performance and safety results from its registrational PATHFINDER 2 study…
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
On Jul. 7, 2025, Celltrion announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab)…
Biotechnology | CDC | COVID-19 | Diagnostics | Disease | Genomics | NIH | Oncology | Radiology | Women's Health
Annual Report to the Nation Shows Cancer Deaths Continue to Decline
On Apr. 21, 2025, the National Institutes of Health (NIH) reported that overall death rates from cancer declined steadily among…
Thousands of people could benefit from new twice-a-day tablet for advanced breast cancer
On Apr. 11, 2025, the UK National Institute for Health and Care Excellence (NICE) recommended capivasertib (also called…
Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer
On Jan. 10, 2025, researchers at Roswell Park Comprehensive Cancer Center have identified a previously unknown cause of…
U.S. Surgeon General Issues New Advisory on Link Between Alcohol and Cancer Risk
On Jan. 3, 2025, the U.S. General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Alcohol…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences and Cleveland Clinic Presented Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine
On Nov. 8, 2024, Anixa Biosciences announced updated positive data from the Phase 1 clinical trial of its…
Biotechnology | Disease | FDA | Oncology | Therapeutics
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
On Oct. 10, 2024, Genentech announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib),…
Breast Cancer Mortality Continues Three Decade Decline, but Steeper Increases in Incidence for Women <50
On Oct. 1, 2024, the American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update…
Biotechnology | COVID-19 | Diagnostics | NIH | Oncology | Therapeutics | Women's Health
New cancer diagnoses did not rebound as expected following pandemic
On Sept. 24, 2024, researchers at the National Institutes of Health (NIH) reported results of a study that…
Breast and ovarian cancer linked to thousands of gene variants
On Sept. 18, 2024, researchers from the Wellcome Sanger Institute and their collaborators reported that they had identified…
False-positive mammogram results discourage some women from future screenings
On Sept. 3, 2024, a major study led by the UC Davis Comprehensive Cancer Center (UC DAVIS) has…
Biotechnology | Diagnostics | Disease | NIH | Oncology | Radiology | Therapeutics | Women's Health
NCI’s Cancer Trends Progress Report announced 2023 Incidence and Mortality Data
On Sep. 3, 2024, the National Cancer Institute (NCI) announced that the latest Cancer Trends Progress Report included…
Generation X and Millennials in U.S. Have Higher Risk of Developing 17 Cancers Compared to Older Generations
On Jul. 31, 2024, a large study led by researchers at the American Cancer Society (ACS) suggested incidence…
Biotechnology | Diagnostics | Disease | Oncology | Therapeutics | WHO
Nearly 1.8 billion adults at risk of disease from not doing enough physical activity
On Jun. 26. 2024, the World Health Organization reported that new data show that nearly one third (31%)…
Biotechnology | Disease | Life Science History | NIH | Oncology | Radiology | Therapeutics | Women's Health
American Association for Cancer Research released biennial Cancer Disparities Progress Report 2024
On May 15, 2024, the American Association for Cancer Research (AACR) released its biennial Cancer Disparities Progress Report…
U.S. Preventive Services Task Force recommended all women get screened for breast cancer every other year aged 40 to 74
On Apr. 30, 2024, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
On Dec. 6, 2023, Anixa Biosciences announced updated positive results from the Phase 1 clinical trial of its…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA Cleared 23andMe improved BRCA report for communities underrepresented in genetic testing
On Aug. 31, 2023, the U.S. Food and Drug Administration (FDA) cleared for marketing the updated 23andMe Personal…
U.S. Preventive Services Task Force recommended that all women get screened for breast cancer every other year starting at age 40
On May 9, 2023, the U.S. Preventive Services Task Force (USPSTF) recommended that all women get screened for…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA updated mammography regulations to require reporting of breast density information and facility oversight
On Mar. 9, 2023, the U.S. Food and Drug Administration (FDA) announced that it had published updates to…
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics | WHO | Women's Health
WHO launched new roadmap on breast cancer
On Feb. 3, 2023, the World Health Organization (WHO) released an updated Global Breast Cancer Initiative (GBCI) Framework…
Biotechnology | FDA | Oncology | Therapeutics
The FDA approves Genentech’s updated drug labeling for Xeloda (capecitabine) under Project Renewal Pilot Program
On Dec. 24, 2022, the U.S. Food and Drug Administration (FDA) approved updated labeling for Genentech’s capecitabine tablets…
FDA approved first targeted therapy for HER2-low breast cancer
On Aug. 5, 2022, the U.S. Food and Drug Administration (FDA) approved Daiichi Sankyo’s Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine Technology
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
Major study linked breast cancer treatment with increased risk of cardiovascular disease
On Apr. 6, 2022, a new study in the Journal of Clinical Oncology showed that women receiving certain…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences announced patient dosing of investigational vaccine candidate in first-of-its-kind preventative breast cancer vaccine study
On Oct. 26, 2021, Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it had commenced…
Biotechnology | Disease | Genomics | Oncology
UTSW researchers identified new gene involved in breast cancer growth
On Jan. 12, 2021, a team researchers from the University of Texas Southwestern (UTSW) announced they had identified…
FDA approved Merck’s KEYTRUDA (pembrolizumab) in combination with chemo for patients with TNBC
On Nov. 13, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s…